Flavopiridol pharmacokinetic parameters for patients enrolled in cohort 1
| . | Cohort 1 . | Cohort 3 . | |
|---|---|---|---|
| . | Cycle 1, d 1 . | Cycle 2, d 1 . | |
| No. patients | 20 | 19 | 14 |
| AUC, μM per h | 10.9 ± 6.3 | 11.3 ± 5.2 | 12.7 ± 3.7 |
| CL, L/h/m2 | 14.5 ± 6.5 | 13.6 ± 6.2 | 15.2 ± 5.4 |
| Vd, L/m2 | 267 ± 199 | 270 ± 255 | 294 ± 161 |
| T1/2, h | 14.0 ± 10.2 | 12.6 ± 6.8 | 12.8 ± 3.8 |
| C0.5 h, μM | 1.56 ± 0.92 | 2.21 ± 1.06 | 1.95 ± 0.78 |
| C4.5 h, μM | 0.93 ± 0.54 | 1.03 ± 0.07 | 1.54 ± 0.48 |
| . | Cohort 1 . | Cohort 3 . | |
|---|---|---|---|
| . | Cycle 1, d 1 . | Cycle 2, d 1 . | |
| No. patients | 20 | 19 | 14 |
| AUC, μM per h | 10.9 ± 6.3 | 11.3 ± 5.2 | 12.7 ± 3.7 |
| CL, L/h/m2 | 14.5 ± 6.5 | 13.6 ± 6.2 | 15.2 ± 5.4 |
| Vd, L/m2 | 267 ± 199 | 270 ± 255 | 294 ± 161 |
| T1/2, h | 14.0 ± 10.2 | 12.6 ± 6.8 | 12.8 ± 3.8 |
| C0.5 h, μM | 1.56 ± 0.92 | 2.21 ± 1.06 | 1.95 ± 0.78 |
| C4.5 h, μM | 0.93 ± 0.54 | 1.03 ± 0.07 | 1.54 ± 0.48 |
Cohort 1 consisted of a 30 mg/m2 bolus plus a 30 mg/m2 4-hour infusion; n = 20. AUC indicates area under the plasma concentration time curve from time 0 to infinity; CL, total systemic clearance; Vd, volume of distribution, T1/2, terminal elimination half-life; C0.5 h, flavopiridol plasma concentration obtained 0.5 h after starting the bolus infusion (ie, end of the 0.5-h bolus infusion); and C4.5 h, flavopiridol plasma concentration obtained 4.5 h after starting the bolus infusion (ie, end of the 4-h continuous infusion). Values are presented as means ± standard deviation.